FORM 10-QSB
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

    For the quarterly period ended March 31, 2007

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
    EXCHANGE ACT OF 1934

                            Commission File No: 09081

                                   CYBRDI INC.
                                   -----------
             (Exact name of registrant as specified in its charter)

CALIFORNIA                                               95-2461404
----------                                               ----------
(State or other jurisdiction of                          (I.R.S. Employer ID No)
incorporation or organization)

                      401 Rosemont Ave. Frederick, MD 21701
                      -------------------------------------
                     (Address of principal executive office)

                  Registrant's telephone number: (301) 644-3901

                                       N/A
      ---------------------------------------------------------------------
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [ ] No [x]

Indicate by a check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [x]

Indicate by a check mark whether the registrant is a shell Company (as defined
by Rule 12b-2 of the Act).

Yes [ ]     No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date:

50,456,569 shares of Common Stock, without par value, as of May 18, 2007

<PAGE>
                                      INDEX

                        PART I. - FINANCIAL INFORMATION              PAGE NUMBER
                                                                     -----------

Item 1. Financial Statements

Consolidated Balance Sheets
  (Unaudited) as at March 31, 2007 and (Audited) December 31, 2006...........1

Consolidated Statements of Operations
  (Unaudited) For the Three Months Ended March 31, 2007 and 2006.............2

Consolidated Statements of Cash Flow
  (Unaudited) For the Three Months Ended March 31, 2007 and 2006.............3

Notes to Consolidated Financial Statements (Unaudited).......................4

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operation.................................................8

Item 3. Quantitative and Qualitative Disclosures about Market Risk...........11

Item 4. Controls and Procedures..............................................16

                          PART II. - OTHER INFORMATION

Item 1. Legal Proceedings....................................................16

Item 2. Unregistered Sales of Equity Securities..............................16

Item 3. Defaults upon senior securities......................................16

Item 4. Submission of matters to a vote of security holders..................17

Item 5. Exhibits and reports on Form 8-K.....................................17


<PAGE>

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-QSB for the quarterly period ended March 31,
2007 contains "forward-looking statements". Generally, the words "believes",
"anticipates," "may," "will," "should," "expect," "intend," "estimate,"
"continue," and similar expressions or the negative thereof or comparable
terminology are intended to identify forward-looking statements which include,
but are not limited to, statements concerning the Company's expectations
regarding its working capital requirements, financing requirements, business
prospects, and other statements of expectations, beliefs, future plans and
strategies, anticipated events or trends, and similar expressions concerning
matters that are not historical facts. Such statements are subject to certain
risks and uncertainties, including the matters set forth in this Quarterly
Report or other reports or documents the Company files with the Securities and
Exchange Commission from time to time, which could cause actual results or
outcomes to differ materially from those projected. Undue reliance should not be
placed on these forward-looking statements which speak only as of the date
hereof. The Company undertakes no obligation to update these forward-looking
statements. In addition, the forward-looking statements in this Quarterly Report
on Form 10-QSB involve known and unknown risks, uncertainties and other factors
that could cause the actual results, performance or achievements of the Company
to differ materially from those expressed in or implied by the forward-looking
statements contained herein.

<PAGE>

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                          CYBRDI, INC. AND SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                    MARCH 31, 2007   DECEMBER 31, 2006
                                                                    --------------   -----------------
                                                                      (UNAUDITED)         (AUDITED)
<S>                                                                   <C>              <C>
                                 ASSETS

CURRENT ASSETS
     Cash and equivalents                                             $   759,342      $   782,899
     Accounts receivable                                                    1,262           37,382
     Inventories                                                          374,647          366,161
     Loan to unaffiliated company                                       3,275,844        3,241,886
     Other receivables and prepaid expenses                               232,794          200,384
                                                                      -----------      -----------
TOTAL CURRENT ASSETS                                                    4,643,889        4,628,712
PROPERTY, PLANT AND EQUIPMENT, NET                                        491,020          505,714
INTANGIBLE ASSETS, NET                                                    504,139          519,415
                                                                      -----------      -----------

TOTAL ASSETS                                                            5,639,048        5,653,841
                                                                      ===========      ===========
                     LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
     Accounts payable and accrued expenses                                136,195          133,463
     Other payables                                                        38,827           31,508
     Amount due to stockholders/officers                                  187,311          205,218
                                                                      -----------      -----------
TOTAL CURRENT LIABILITIES                                                 362,333          370,189

MINORITY INTERESTS                                                      1,127,488        1,124,557
                                                                      -----------      -----------

TOTAL LIABILITIES                                                       1,489,821        1,494,746
                                                                      -----------      -----------

STOCKHOLDERS' EQUITY
     Preferred Stock, $1.00 per value, 500,000 shares authorized,
        zero shares issued and outstanding                                     --
     Common Stock, no par value, 150,000,000 shares authorized,
        50,456,569 shares issued and outstanding                               --
     Additional paid-in capital                                         3,601,932        3,601,932
     Reserve funds                                                        336,885          336,885
     Accumulated deficit                                                  (60,862)         (12,639)
     Accumulated other comprehensive income                               271,272          232,917
                                                                      -----------      -----------
TOTAL STOCKHOLDERS' EQUITY                                              4,149,227        4,159,095

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                            $ 5,639,048      $ 5,653,841
                                                                      ===========      ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       1
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
               CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
<TABLE>
<CAPTION>
                                                  FOR THREE MONTHS ENDED MARCH 31,
                                                  --------------------------------
                                                      2007              2006
                                                  ------------      ------------
                                                   (UNAUDITED)       (UNAUDITED)
<S>                                               <C>               <C>
REVENUE
      Products                                    $    168,096      $     83,218
      Service rendered                                   9,179            15,121
                                                  ------------      ------------
         TOTAL REVENUE                                 177,275            98,339
                                                  ------------      ------------
COST OF SALES
      Products                                          77,439            43,522
      Service rendered                                       5                90
                                                  ------------      ------------
        TOTAL COST OF SALES                             77,444            43,612
                                                  ------------      ------------
GROSS PROFIT                                            99,831            54,727
                                                  ------------      ------------

OPERATING EXPENSES:
      Selling and distribution expenses                 27,055            28,624
      General and administrative expenses              164,674           139,406
                                                  ------------      ------------
TOTAL OPERATING EXPENSES                               191,729           168,030
                                                  ------------      ------------

LOSS FROM OPERATIONS                                   (91,898)         (113,303)
                                                  ------------      ------------

OTHER INCOME/(EXPENSE)
      Interest income                                   43,019            61,441
      Other income, net                                  3,587             2,527
                                                  ------------      ------------
TOTAL OTHER INCOME                                      46,606            63,968
                                                  ------------      ------------

LOSS BEFORE INCOME TAXES                               (45,292)          (49,335)
Income Taxes Expenses                                       --                --
                                                  ------------      ------------
Loss before Minority Interest                          (45,292)          (49,335)
Minority Interest/(Loss)                                 2,931            (2,567)
                                                  ------------      ------------
NET LOSS                                          $    (48,223)     $    (46,768)
                                                  ============      ============

Other Comprehensive Income (Loss):
Foreign Currency Translation gain                       38,355            24,344
                                                  ------------      ------------
COMPREHENSIVE LOSS                                $     (9,868)     $    (22,424)
                                                  ============      ============

Net Loss Per Common Share
      Basic and Diluted                           $      (0.00)     $      (0.00)
                                                  ============      ============

Weighted Average Number of Shares Outstanding
      Basic and Diluted                             50,456,569        50,456,569
                                                  ============      ============
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       2
<PAGE>
                          CYBRDI, INC. AND SUBSIDIARY
               CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

<TABLE>
<CAPTION>
                                                                FOR THREE MONTHS ENDED MARCH 31,
                                                                --------------------------------
                                                                     2007             2006
                                                                 -----------      -----------
                                                                 (UNAUDITED)      (UNAUDITED)
<S>                                                              <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES
     NET LOSS                                                    $   (48,223)     $   (46,768)
     ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH
       PROVIDED BY OPERATING ACTIVITIES:
         Depreciation and amortization                                42,106           34,600
         Minority interest                                             2,931           (2,567)
         Imputed rental income                                            --               --
     CHANGES IN OPERATING ASSETS AND LIABILITIES:
         Accounts receivable                                          36,133           30,453
         Inventories                                                  (4,602)         (43,909)
         Other receivable and prepaid expenses                       (29,997)         (64,532)
         Accounts payable and accrued expenses                         1,320           21,201
         Other payables                                                6,917           (3,630)
                                                                 -----------      -----------
     NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES               6,585          (75,152)
                                                                 -----------      -----------

CASH FLOWS FROM INVESTING ACTIVITIES
         Purchase of property, plant and equipment                    (1,641)          (1,584)
         Loan to unaffiliated companies                                   --       (3,654,870)
                                                                 -----------      -----------
     NET CASH USED IN INVESTING ACTIVITIES                            (1,641)      (3,656,454)
                                                                 -----------      -----------

CASH FLOWS FROM FINANCING ACTIVITIES
         Proceeds from shareholders/officers                           3,323               --
         Payment to shareholders/officers                            (17,146)         (15,459)
                                                                 -----------      -----------
     NET CASH USED IN FINANCING ACTIVITIES                           (13,823)         (15,459)
                                                                 -----------      -----------

NET DECREASE IN CASH AND EQUIVALENTS
     Net Decrease in Cash and Equivalents                             (8,879)      (3,747,065)
     Effect of Exchange Rate Changes on Cash and Equivalents         (14,678)          12,070
     Cash and Equivalents, at Beginning of Period                    782,899        4,206,695
                                                                 -----------      -----------

     CASH AND EQUIVALENTS, AT END OF PERIOD                      $   759,342      $   471,700
                                                                 ===========      ===========
</TABLE>

              The accompanying notes are an integral part of these
                       consolidated financial statements.

                                       3
<PAGE>
                           CYBRDI, INC. AND SUBSIDIARY
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A - BASIS OF PRESENTATION

1. INTERIM FINANCIAL STATEMENTS

The unaudited consolidated financial statements of Cybrdi Inc. and subsidiary
(the "Company") have been prepared in accordance with U.S. generally accepted
accounting principles for interim financial information and pursuant to the
requirements for reporting on Form 10-QSB. Accordingly, they do not include all
the information and footnotes required by accounting principles generally
accepted in the United States of America for annual financial statements.
However, the information included in these interim financial statements reflects
all adjustments (consisting solely of normal recurring adjustments) which are,
in the opinion of management, necessary for the fair presentation of the
consolidated financial position and the consolidated results of operations.
Results shown for interim periods are not necessarily indicative of the results
to be obtained for a full year. The consolidated balance sheet information as of
December 31, 2006 was derived from the audited consolidated financial statements
included in the Company's Annual Report on Form 10-KSB. These interim financial
statements should be read in conjunction with that report.

The consolidated financial statements include the accounts of Cybrdi, Inc. and
its wholly-owned subsidiaries and joint ventures. All material intercompany
balances and transactions have been eliminated.

2. DESCRIPTION OF BUSINESS

Cybrdi, Inc. (f/k/a Certron Corporation) (the "Company" or "Cybrdi") was
incorporated on August 1, 1966, under the laws of the State of California. Until
June 2004, the Company's business focused primarily on the distribution of
magnetic media products, primarily blank audio and video cassettes. Due to
continuing intense price competition and technological changes in the
marketplace for its products, the Company lost its remaining significant
customers and as a result, disposed of and wrote off its remaining inventory. As
a result of these occurrences, the Company concluded that its audio and
videotape businesses were no longer viable and that some of its product lines
were obsolete, thus the Company switched its business focus on attempting to
find a buyer for the Company.

In November 2004, the Company, through Certron Acquisition Corp., a newly formed
Maryland corporation and wholly-owned subsidiary of the Company ("Acquisition
Sub") acquired all of the outstanding shares of Cybrdi, Inc., a privately held
company incorporated in the State of Maryland ("Cybrdi Maryland"). The Company
acquired Cybrdi Maryland in exchange for 47,328,263 shares of common stock of
the Company. Subsequent to the merger, the former shareholders of Cybrdi
Maryland receivedapproximately 93.8% of the outstanding shares of the Company's
common stock. As a result of the ownership interests by the former shareholders
of Cybrdi Maryland, for financial statement reporting purposes, the merger was
treated as a reverse acquisition, with Cybrdi Maryland deemed the accounting
acquirer and Centron Corporation deemed the accounting acquiree. Historical
information of the surviving company is that of Cybrdi Maryland.

Cybrdi Maryland was established in 2001 to acquire an interest in biogenetic
products commercialization and related services entities in Asia. On March 5,
2003, Cybrdi Maryland acquired an 80% interest of the Shaanxi Chao Ying
Biotechnology Co., Ltd. ("Chaoying Biotech"), a sino-foreign equity joint
venture established in July 2000 in the People's Republic of China ("PRC"),
through the exchange of 99% of the Company's shares to the existing shareholders
of Chaoying Biotech. For financial statement reporting purposes, the merger was
treated as a reverse acquisition, with Chaoying Biotech deemed the accounting
acquirer and Cybrdi Maryland deemed the accounting acquiree.

                                       4
<PAGE>

Chaoying Biotech is a sino-foreign equity joint venture between Shaanxi Chao
Ying Personal Care Group Ltd. (the "Chinese Partner", a PRC corporation) and
Immuno-OncoGenomics Inc. (the "Foreign Partner", a USA corporation). The joint
venture agreement has a 15 year operating period which began in July 2000 and
the agreement is extendable upon mutual consent of both partners. The principal
activities of Chaoying Biotech are research, manufacture and sale of various
high-quality tissue arrays and the related services in the PRC.

Most of the Company's activities are conducted through Chaoying Biotech.
Chaoying Biotech, with its principal operations located in China, aims to take
advantage of China's abundant scientific talent, low wage rates, less stringent
biogenetic regulation, and the huge genetic population as it introduces its
growing list of tissue micro array products.

On February 10, 2005, the Company completed the merger with Cybrdi Maryland and
changed its name to Cybrdi, Inc.

3. USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ materially from those
estimates.

4. REVENUE RECOGNITION

Revenue represents the invoiced value of goods sold recognized upon the delivery
of goods to customers and service income is recognized when services are
provided. Deferred revenue represents the undelivered portion of invoiced value
of goods sold to customers. Sales transactions not meeting all the conditions of
the full accrual method are accounted for using the deposit method of
accounting. Under the deposit method, all costs are capitalized as incurred, and
payments received from the buyer are recorded as customer deposits.

5. REVERSE MERGER

On February 10, 2005, (the "Closing Date") the Company, closed the transactions
contemplated by an Agreement and Plan of Merger (the "Agreement") among Certron
Corporation ("Certron"), a California corporation, Certron Acquisition Corp., a
Maryland corporation and a wholly-owned subsidiary of Certron ("Acquisition
Sub"), and Cybrdi, Inc., a Maryland corporation ("Cybrdi - Maryland") relating
to the acquisition by Certron of all of the issued and outstanding capital stock
of Cybrdi - Maryland in exchange for shares of common stock of Certron
representing approximately 93.8% of the issued and outstanding common stock of
Certron. Pursuant to the terms of the Agreement, on the Closing Date (a)
Acquisition Sub merged with and into Cybrdi - Maryland, with Cybrdi - Maryland
being the surviving corporation, (b) the common stock of Cybrdi-Maryland was
cancelled and converted into the right to receive shares of the common stock of
Certron at an exchange ratio of 1.566641609 This resulted in the issuance of
47,328,263 shares of the Certron's common stock , and (c) each share of the
common stock of Acquisition Sub was converted into one share of the common stock
of Cybrdi-Maryland. The share exchange was accounted for as a reverse merger
under the purchase method of accounting. Accordingly, Cybrdi Inc. is treated as
the continuing entity for accounting purposes and the historical financial
statements presented will be those of Cybrdi, Inc.

                                       5
<PAGE>

In connection with the Agreement, on February 10, 2005, the Company amended its
articles of incorporation to authorize the issuance of 150,000,000 shares of
common stock, no par value and 500,000 shares of preferred stock, $1.00 par
value per share. There are currently no shares of preferred stock issued or
outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company's then
existing officers and directors tendered their resignation and Yanbiao Bai was
appointed as our Chairman of the Board of Directors. Mr. Bai then nominated the
remaining current directors to serve on the Board of Directors. On March 31,
2005 the Company's Board of Directors changed its fiscal year end from October
31 to December 31. Certron's fiscal year end was changed to correspond with the
fiscal year end of Cybrdi - Maryland.

6. GOVERNMENT GRANT

In 2000, the P.R. China Government launched the "Western Development Project"
which, as part of the project, included the development of 15 specifically named
technologies and has allocated government grants to encourage the development of
these technologies. For the fiscal quarters ended March 31, 2007 and 2006, the
Company did not receive the government grants under the Western Development
Project. The Company included the government grant in other income, net in the
accompanying statements of operations and comprehensive income/ (loss).

7. RECENT ACCOUNTING PRONOUNCEMENTS

In September 2006, the Financial Accounting Standard Board ("FASB") issued SFAS
No. 157, "Fair Value Measurements," which provides enhanced guidance for using
fair value to measure assets and liabilities. SFAS No. 157 provides a common
definition of fair value and establishes a framework to make the measurement of
fair value in generally accepted accounting principles more consistent and
comparable. SFAS No. 157 also requires expanded disclosures to provide
information about the extent to which fair value is used to measure assets and
liabilities, the methods and assumptions used to measure fair value, and the
effect of fair value measures on earnings. SFAS No. 157 is effective for
financial statements issued in fiscal years beginning after November 15, 2007
and to interim periods within those fiscal years. The Company is currently in
the process of evaluating the effect, if any, the adoption of SFAS No. 157 will
have on its consolidated results of operations, financial position, or cash
flows.

In September 2006, the Securities and Exchange Commission issued Staff
Accounting Bulletin ("SAB") No. 108, "Considering the Effects of Prior Year
Misstatements when Quantifying Misstatements in Current Year Financial
Statements". SAB No. 108 was issued in order to eliminate the diversity in
practice surrounding how public companies quantify financial statement
misstatements. SAB No. 108 requires that registrants quantify errors using both
a balance sheet (iron curtain) approach and an income statement (rollover)
approach, then evaluate whether either approach results in a misstated amount
that, when all relevant quantitative and qualitative factors are considered, is
material. SAB No. 108 is effective for fiscal years ending after November 15,
2006. The Company has adopted the bulletin during 2006. The adoption did not
have a material effect on the consolidated results of operations, financial
position, or cash flows.

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for
Uncertainty in Income Taxes an Interpretation of FASB Statement No. 109" ("FIN
48"). FIN 48 clarifies the accounting for uncertainty in income taxes recognized
in a company's financial statements in accordance with FAS 109, "Accounting for
Income Taxes". FIN 48 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. FIN 48 also provides
guidance on derecognizing, classification, interest and penalties, accounting in
interim periods, disclosure and transition. The requirements of FIN 48 are
effective beginning January 1, 2007.


                                       6
<PAGE>

NOTE B - ASSETS

The March 31, 2007 balance sheet included total current assets of $4,643,889 and
non-current assets of $995,159. Of these amounts, approximately $759,342 in cash
and $1,262 in accounts receivable are planned for funding current operations and
for future business expansion.

Other current assets also included inventories, loan to unaffiliated company,
and other receivable and prepaid expenses. Inventories are mainly finished goods
and very few raw materials, working in process, packaging material, and other..
Inventories are stated at the lower of cost or market. Cost of raw materials is
determined on the basis of first in first out method ("FIFO"). Finished goods
are determined on the weighted average basis and are comprised of direct
materials, direct labor and an appropriate proportion of overhead. The other
primary asset included in-current assets is loan to unaffiliated company. Loan
to unaffiliated company consists of loans to QuanYe Security Co.,Ltd ("QuanYe")
, an unrelated People's Republic of China ("PRC") registered company located in
Xian PRC. QuanYe is engaged in the pawnshop business and their primary business
is offering alternative financing to small local companies. According to the
loan agreement, QuanYe has received loans from Chaoying Biotech of a total
amount of RMB29.3Million (equivalent to $3,793,764,) since January 2006. As of
March 31, 2007, the balance of the loans had been reduced to RMB25.3 Million
(equivalent to $3,275,844) and the details are listed as follows:

<TABLE>
<CAPTION>
     CONTRACT
   EXECUTED DATE                     LOAN AMOUNT              INTEREST           TERM             REPAYMENT DATE
-------------------- ------------------------------------- --------------- ------------------- -----------------------
<S>                        <C>                 <C>               <C>            <C>                  <C>
     1/9/2006              RMB 15,000,000      $1,942,200        8%              1 year              11/16/2006
-------------------- --------------------- --------------- --------------- ------------------- -----------------------
     1/10/2006              RMB 8,300,000      $1,074,684        8%              1 year              11/25/2006
-------------------- --------------------- --------------- --------------- ------------------- -----------------------
     1/19/2006              RMB 6,000,000       $ 776,880        5%             3 months                 **
-------------------- --------------------- --------------- --------------- ------------------- -----------------------
</TABLE>

** RMB1 million (equivalent to $129,480), RMB2 million (equivalent to $258,960)
and RMB1 million (equivalent to $129,480)was repaid on April 28, 2006 ,June 19,
2006 and August 17,2006 respectively. In January 2007, the company re-executed
Loan of RMB 2 million (equivalent to $258,960) was extended to March 31, 2007
with an annual interest rate of 5%. The Company did not extend this loan
agreement, but anticipates having all of these loans (included RMB15.3 Million
and RMB8.3 Million listed below) repaid by QuanYe before June 30, 2007.

On October 9, 2006, Chaoying Biotech renewed the first and second loan
agreements (RMB15 millions and RMB8.3 million) with QuanYe. Due to the influence
of market factors, continuous increase of general and management costs and
relatively lower profit rates of QuanYe. Chaoying Biotech agreed to extend the
term of the first and second loan for an additional 6 months and they are now
due on May 24, 2007, at an adjusted interest rate of 5% (which was reduced from
8% retroactive from the date of the original loan). The details are listed as
follows:

<TABLE>
<CAPTION>
    CONTRACT
RE-EXECUTED DATE                       LOAN AMOUNT                INTEREST        TERM        EXTENDED DUE DATE
------------------------ ------------------------------------- --------------- ------------- --------------------
<S>                      <C>                   <C>             <C>             <C>           <C>
11/25/2006               RMB 15,000,000        $1,942,200      5%              6 months      05/24/2007
------------------------ --------------------- --------------- --------------- ------------- --------------------
11/25/2006               RMB   8,300,000       $1,074,684      5%              6 months      05/24/2007
------------------------ --------------------- --------------- --------------- ------------- --------------------
12/31/2006               RMB   2,000,000       $ 258,960       5%              3 months      03/31/2007
------------------------ --------------------- --------------- --------------- ------------- --------------------
Total                    RMB 25,300,000        $3,275,844
------------------------ --------------------- --------------- --------------- ------------- --------------------
</TABLE>

Management believes and views QuanYe as an alternative financial institution and
it is an optimal way to use its cash on hand. The regular market interest rate


                                       7
<PAGE>

in the PRC is 0.72% per annum. Cybrdi expects to obtain higher interest income
for its unused fund through these types of loan arrangements. However, these
advances are unsecured and have a default risk higher than a bank deposit.

Included in-non-current assets are property, plant and equipment, intangible
assets, and deferred tax assets. Property, plant and equipment mainly consist of
building, motor vehicles, leasehold improvement, software-website, and machinery
used for product manufacturing located in the People's Republic of China
("PRC"), and office equipments located in PRC and United States. . Depreciation
on property, plant and equipment is computed using the straight -line method
over the estimated useful life of the assets. The majority of the assets have
estimated useful lives of 10 years. Building and office equipments have
estimated useful lives of 20 and 5 years, respectively. Intangible assets
include a patent. Effective January 1, 2002, with the adoption of SFAS No. 142,
intangible assets with a definite life are amortized on a straight-line basis.
The patent is being amortized over its estimated life of 10 years.

NOTE C - LIABILITIES

The March 31, 2007 balance sheet included total liabilities of $1,489,822 of
which $1,127,488 represents the 20% minority interest in Chaoying Biotech.
Included in the total liabilities is $187,311 which was due to stockholders who
are also officers of the Company. This amount was deemed an advance to the
Company to assist with operations in prior years. This advance is non-interest
bearing and has no set repayment terms.

In accordance with the relevant tax laws and regulations of the PRC, Chaoying
Biotech is entitled to full exemption from Corporation Income Tax ("CIT") for
the first two years and a 50% reduction in CIT for the next three years,
commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, the Company begins to record 50% CIT provision for first
quarter of 2005. The effective tax rate is approximately 7.5%. Since there is no
taxable income, no income taxes provision required as of March 31, 2007 and
2006, respectively.

NOTE D - STOCKHOLDERS' EQUITY

As a result of the reverse merger (see Note A), the common stock of
Cybrdi-Maryland has been cancelled and converted into shares of common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of Certron's common stock to the Cybrdi shareholders. As of
March 31, 2007, the Company had 50,456,569 shares of common stock issued and
outstanding. Historical information of the surviving company is that of Cybrdi -
Maryland.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
        RESULTS OF OPERATION

The following discussion and analysis should be read in conjunction with our
Financial Statements and Notes thereto appearing elsewhere in this Report on
Form 10-QSB as well as our other SEC filings.

PLAN OF OPERATIONS

We focus on biogenetics commercialization and healthcare product applications.
Our primary business includes sales of tissue microarray products and services.
Tissue chips, also called microtissue arrays, provide high-throughput molecular
profiling and parallel analysis of biological and molecular characteristics for
hundreds of pathologically controlled tissue specimens. Tissue arrays can
provide rapid and cost-effective localization and evaluation of proteins, RNA,
or DNA molecules, which is particularly useful for functioning genomic studies.


                                       8
<PAGE>

Cybrdi manufactures both human and animal tissue microarray for a wide variety
of scientific uses, including drug discovery and development purposes.

Our business strategy and objectives for the near future include

    o    Enhancing research and development in TMAs and technical service
    o    Expanding our product portfolio and virtual tissue array data bank
         (vTMAB)
    o    Launch the health diagnosis kit for obesity and skin disease

With our research in genes, we can provide professional health diagnostic
service for our customers. Through our genetic analysis, we can research reasons
for obesity and other skin diseases like freckles. This offers a more accurate
and specialized diagnosis. It can assist a customer with setting up the
appropriate health or fitness program. We are the first and only company that
can provide genetic testing for the mechanism of obesity or skin disease.
We will also explore other business development opportunities that can help
leverage our sales platform and relationship with affiliated companies. Until
such time as we can identify attractive marketing opportunities, we will loan
available cash on a short term unsecured basis to non-affiliated third parties
in order to generate interest income.

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2007 COMPARED TO THREE MONTHS ENDED MARCH 31, 2006

<TABLE>
<CAPTION>
                                                 FOR THREE MONTHS ENDED MARCH 31,
                                         ------------------------------------------------                     2007 VS 2006
                                              2007           COST            2006             COST       INCREASE/ (DECREASE)
                                         ---------------       %   ----------------------      %    ---------------------------
                                            UNAUDITED                      UNAUDITED
<S>                                           <C>           <C>                 <C>          <C>          <C>          <C>
REVENUE
      Products                                $ 168,096                         $ 83,218                   84,878      101.99%
      Service rendered                            9,179                           15,121                   (5,942)     -39.30%
                                         ---------------           ----------------------           --------------
         TOTAL REVENUE                          177,275                           98,339                   78,936       80.27%
                                         ---------------           ----------------------           --------------
COST OF SALES
      Products                                   77,439     46.07%                43,522     52.30%        33,917       77.93%
      Service rendered                                5      0.05%                    90      0.09%           (85)     -94.44%
                                         ---------------           ----------------------           --------------
        TOTAL COST OF SALES                      77,444                           43,612                   33,832       77.57%
                                         ---------------           ----------------------           --------------
GROSS PROFIT                                     99,831                           54,727                   45,104       82.42%
                                         ---------------           ----------------------           --------------
GROSS PROFTI PERCENTAGE                          56.31%                           55.65%
OPERATING EXPENSES:
      Selling and distribution expenses          27,055                           28,624                   (1,569)      -5.48%
      General and administrative expenses       164,674                          139,406                   25,268       18.13%
                                         ---------------           ----------------------           --------------
TOTAL OPERATING EXPENSES                        191,729                          168,030                   23,699       14.10%
                                         ---------------           ----------------------           --------------
LOSS FROM OPERATIONS                            (91,898)                        (113,303)                  21,405      -18.89%
                                         ---------------           ----------------------           --------------
OTHER INCOME/(EXPENSE)
      Interest income                            43,019                           61,441                  (18,422)     -29.98%
      Other income, net                           3,587                            2,527                    1,060       41.95%
                                         ---------------           ----------------------           --------------
TOTAL OTHER INCOME                               46,606                           63,968                  (17,362)     -27.14%
                                         ---------------           ----------------------           --------------
LOSS BEFORE INCOME TAXES                        (45,292)                         (49,335)                   4,043       -8.20%
Income Taxes Expenses                                 -                                -                        -
                                         ---------------           ----------------------           --------------
Loss before Minority Interest                   (45,292)                         (49,335)                   4,043       -8.20%
Minority Interest/(Loss)                          2,931                           (2,567)                   5,498     -214.20%
                                         ---------------           ----------------------           --------------
NET (LOSS) INCOME                             $ (48,223)                       $ (46,768)                  (1,455)       3.11%
                                         ===============           ======================           ==============
</TABLE>

                                       9
<PAGE>

NET SALES

We generate two categories of revenues: tissue chip product and services. The
net sales increased $78,936 to $177,275 for the three months ended March 31,
2007 from $98,339 for the three months ended March 31, 2006.

Tissue Chip Product: The net sales increased $84,878 to $168,096 for the three
months ended March 31, 2007 as compared to $83,218 for the three months ended
March 31, 2006. International sales volume for Tissue Chip Products increased
for the three months ended March 31, 2007 as compared to March 31, 2006.

Beginning in 2006, tissue chip sales in China became more competitive, with some
former customers in China, especially medical colleges and hospitals, have
become capable of making tissue array products by themselves. Accordingly our
sales decreased in China with higher unit sales price, and increased our sales
in the United States with lower unit sales price.

Services: Fewer technical service orders were received during the first quarter
of 2007 as compared to 2006 resulting in a decrease in sales of $5,942 to $9,179
from $15,121 for the three months ended March 31, 2007 as compared to March 31,
2006. We believe that this decline is primarily attributable to increased
competition from larger and better financed multinational companies that can
compete on the basis of name recognition and pricing. We believe that we will be
able to compete in the future based upon the quality of service we can provide.

GROSS MARGIN

Gross margin as a percent of sales was similar (56%) for the three months ended
March 31, 2007 and 2006, respectively. Gross profit for the three months ended
March 31, 2007 increased to $99,831 from $54,727 for the three months ended
March 31, 2006. The primary reason for the increase is increased international
sales of tissue chip products.

OPERATING EXPENSES

Our operating expenses increased to $191,729 for the three months ended March
31, 2007 from $168,030 for the three months ended March 31, 2006. This is
primarily due to an increase in general and administrative expenses of $25,268
to $164,675 for the three months ended March 31, 2007 from $139,406 for the
three months ended March 31, 2006 as well as an decrease in selling and
distribution expenses of $1,569 to $27,055 for the three months ended March 31,
2007 from $28,624 for the three months ended March 31, 2006. The increase in
general and administrative expenses was primarily attributable to the increase
of professional fees in the first quarter 2007.

OTHER INCOME

Interest income reduced $18,422 to $43,019 for the three months ended March 31,
2007 as compared to $61,441for the three months ended March 31, 2006. Interest
income is primarily due to loans which we have made to QuanYe The decrease in
interest income was primarily attributable to the reduction of the interest rate
of these loans.

INCOME TAXES

The Company has not recorded a provision for federal income tax for quarter
ended March 31, 2007 due to no taxable income in the first quarter of 2007 and
2006. In accordance with the relevant tax laws and regulations of the People's


                                       10
<PAGE>

Republic of China, Chaoying Biotech is entitled to full exemption from
Corporation Income Tax ("CIT") for the first two years and a 50% reduction in
CIT for the next three years, commencing from the first profitable year after
offsetting all tax losses carried forward from the previous five years. Since
2003 was Chaoying Biotech's first profitable year, the Company began to record
50% CIT provision as the first quarter of 2005. The effective income tax rate is
7.5% for the quarter ended March 31, 2007 and 2006. Due to operating losses for
the first quarter of 2007 and 2006, the Company does not need to pay income tax
for the quarter ended March 31, 2007 and 2006.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital (total current asset deduct total current liabilities)
increased by $23,033 from $4,281,556 as of March 31, 2007 to $4,258,523 as of
March 31, 2006. The increase was primarily due to the increase in inventories,
and other receivables and prepaid expenses, and the decrease in accounts payable
and accrued expenses, and other payables. For these reasons, we had positive
cash provided by our operating activities for the first quarter of 2007 compared
to negative cash used in the operating activities for the first quarter of 2006.
Accordingly, we believe we have sufficient capital resources to fund our
business.

For investing activities, we had $1,641 and $1,584 respectively in capital fixed
assets expenditures for the three months ended March 31, 2007 and 2006. In order
to earned more interest income, we also issued several loans to QuanYe during
the first quarter of 2006.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-QSB contain or may
contain forward-looking statements that are subject to known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
forward-looking statements were based on various factors and were derived
utilizing numerous assumptions and other factors that could cause our actual
results to differ materially from those in the forward-looking statements. These
factors include, but are not limited to, economic, political and market
conditions and fluctuations, government and industry regulation, interest rate
risk, U.S. and global competition, and other factors. Most of these factors are
difficult to predict accurately and are generally beyond our control. You should
consider the areas of risk described in connection with any forward-looking
statements that may be made herein. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this report. Readers should carefully review this quarterly report in its
entirety, including but not limited to our financial statements and the notes
thereto. Except for our ongoing obligations to disclose material information
under the Federal securities laws, we undertake no obligation to release
publicly any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

RISK FACTORS

There had been no material changes in our risk factors from those disclosed in
our 2006 annual report on Form 10KSB.

                                       11
<PAGE>

You should consider each of the following risk factors and any other information
set forth in this Form 10-QSB and our other reports that we have filed with the
Securities and Exchange Commission ("SEC"), including the Company's financial
statements and related notes, in evaluating the Company's business and
prospects. The risks and uncertainties described below are not the only ones
that impact on the Company's operations and business. Additional risks and
uncertainties not presently known to the Company, or that the Company currently
considers immaterial, may also impair its business or operations. If any of the
following risks actually occur, our business and financial condition, results or
prospects could be harmed.

RISKS ASSOCIATED WITH THE COMPANY'S PROSPECTIVE BUSINESS AND OPERATIONS

The Company has a limited history with respect to the manufacture, sale and
distribution of TMAs. Medical technology is constantly evolving and there can be
no assurance that our TMAa will keep pace with medical breakthroughs. The
Company's ability to achieve and maintain profitability and positive cash flow
over time will be dependent upon, among other things, its ability to (i)
continue to develop new TMA products and market these products both in China and
other developing companies and (ii) its ability to evaluate the merits of
pursuing the beauty supply business and its success in developing franchise
opportunities despite no prior experience.

OUR BUSINESS IS HEAVILY DEPENDENT ON THE ECONOMIC GROWTH OF CHINA

Our business is heavily dependent on the economy and developing middle and upper
class in China. Should the country suffer an economic downturn or should the
government imposed restrictions on the growth of private companies and the
ability of a large consumer class to earn money in the private sector our
business will suffer. To the extent that any of the foregoing should occur, our
revenues will decline significantly.

WE HAVE LOANED OVER $3 MILLION TO NON-AFFILIATED THIRD PARTIES
In order to maximize returns on available cash, the Company has outstanding
unsecured loans totaling approximately $3.2 million, representing approximately
69% of the Company's assets. The loans were placed to secure additional interest
income. However, in the event of a default, the Company risks substantial losses
of their ability to continue to finance ongoing operations. A portion of the
loan in the amount of $258,960 (equivalent to RMB 2,000,000) was due on March 31
but not paid and the balance is due May 24, 2007. Quan Ye is expected to pay the
outstanding balance on or before June 30, 2007. Litigation could be costly to
enforce the loan obligations and may deprive the Company of the use of the cash
for a significant period of time.

WE MAY NOT BE ABLE TO SUPPORT OUR OPERATIONS THROUGH INTERNAL GROWTH

In order to fully implement our business plan, we may require additional
financing. Financing may be in the form of traditional bank financing or through
the sale of our common stock. There can be no assurance that we will be able to
secure adequate bank financing or if available, will be on terms acceptable to
the Company. If we attempt to sell shares of our common stock, existing
shareholders will face dilution and likely a reduction in the price of our
common stock. There are currently no financing arrangements in place.

OUR BUSINESS MAY BE AFFECTED BY UNEXPECTED CHANGES IN REGULATORY REQUIREMENTS IN
THE JURISDICTIONS IN WHICH WE OPERATE.

Development and distribution of our TMA's is subject to regulation both where we
manufacture and where we sell the products. We believe that we are currently in
compliance with applicable governmental rules and procedures. However, there can


                                       12
<PAGE>

be no assurance that changes in the regulatory environment will not make it
difficult for us to comply or result in a substantial increase in our operating
costs and a resulting decline in our margins.

THERE IS UNCERTAINTY AS TO OUR ABILITY TO CONTROL COSTS AND EXPENSES.

If our business grows, costs will increase. Management cannot accurately project
or give any assurance, with respect to its ability to control development and
operating costs and/or expenses in the future. Consequently, even if the Company
is successful in expanding its operations (of which there can be no assurance),
our management still may not be able to control costs and expenses adequately,
and therefore such expansion may result in operating losses. Likewise, if we
have reduced revenues like we had this past year, there can be no assurance that
we will be able to reduce our expenses to offset any decline in revenues.

COMPETITION

Our market is highly competitive and some of our competitors may have greater
resources than us. These competitors may be able to respond more quickly to new
or emerging technologies and changes in customer requirements and devote greater
resources to develop, promote and sell their services. If this should occur,
revenues may decline and we will likely lose our market share.

IF WE DO NOT MANAGE OUR GROWTH, WE MAY NOT BE ABLE TO OPERATE OUR BUSINESS
EFFECTIVELY.

We expect significant expansion will be required to address potential growth in
our customer base, the breadth of our service offerings, and other
opportunities. This expansion could strain our management, operations, systems
and financial resources. To manage any future growth of our operations and
personnel, we must improve and effectively utilize operational, management,
marketing and financial systems and successfully recruit, hire, train and manage
personnel and maintain close coordination among our technical, finance,
marketing, sales and recruitment staffs. We also will need to manage an
increasing number of complex relationships with customers, strategic partners,
advertisers and other third parties. Our failure to manage growth could disrupt
our operations and ultimately prevent us from generating the revenue we expect.

UNANTICPATED OBSTACLES TO EXECUTION OF OUR BUSINESS PLAN.

The Company's business plans may change significantly. Many of the Company's
potential business endeavors are capital intensive and may be subject to
statutory or regulatory requirements. Management believes that the Company's
chosen activities and strategies are achievable in light of current economic and
legal conditions with the skills, background, and knowledge of the Company's
principals and advisors. Management reserves the right to make significant
modifications to the Company's stated strategies depending on future events.

CERTAIN POLITICAL AND ECONOMIC CONSIDERATIONS RELATING TO THE PRC COULD
ADVERSELY AFFECT OUR COMPANY.

The government of the People's Republic of China has welcomed foreign investment
and the expansion of business opportunities in the private sector. There can be
no assurance that this policy will continue or alternatively, that this policy
will not be modified to make it more restrictive to transfer funds from China to
the United States or any other country. Moreover, political instability could
adversely impact our ability to fully implement our business plan as political
instability would likely lead to a downturn in the Chinese economy.

                                       13
<PAGE>

CURRENCY EXCHANGE

Changes in the exchange rate of the Chinese yuan renminbi (CYN) may adversely
impact our profitability. If the CYN declines with respect to the U. S. dollar,
our profitability will be adversely affected.

RESEARCAH AND DEVELMENT CAN BE COSTLY

Medical advances are taking place at a rapid pace. In order to stay competitive
and to provide improved TMAs to the market at competitive prices, we will be
required to continue to devote significant resources to research and
development. There can be no assurance that we will have sufficient cash flow to
make this commitment on a going forward basis.

RELIANCE ON CURRENT MANAGEMENT

We are reliant on our current management team to help us fully implement our
business plan. The loss of any of their services could have a material adverse
impact on the implementation of our business plan and our future growth. We do
not carry any type of key man insurance. During this past year, Dr. Liu resigned
as a director for personal reasons. However, Dr, Liu has agreed to continue to
run our US operations. We have not yet filled this vacancy on our Board of
Directors created by the resignation of Dr. Liue.

The Company's business may experience periods of rapid growth that will place
significant demands on its managerial, operational and financial resources. In
order to manage this possible growth, the Company must continue to improve and
expand its management, operational and financial systems and controls. The
Company will need to expand, train and manage its employee base. No assurances
can be given that the Company will be able to timely and effectively meet such
demands.

WE MAY HAVE DIFFICULTY ATTRACTING QUALIFIED PERSONNEL IN FOREIGN COUNTRIES.

Our research and development program requires us to recruit highly skilled
personnel. There can be no assurance that we will be able to attract these
personnel for work either in the United States or China. If we cannot attract
skilled personnel, our operations will likely suffer and any competitive edge
that we have in the marketplace will quickly erode.

CORPORATE GOVERNANCE MATTERS

We have not voluntarily implemented various corporate governance measures which
may provide shareholders with more protections against interested director
transactions, conflicts of interest and similar matters.

Recent Federal legislation, including the Sarbanes-Oxley Act of 2002, has
resulted in the adoption of various corporate governance measures designed to
promote the integrity of the corporate management and the securities markets.
Some of these measures have been adopted in response to legal requirements.
Others have been adopted by companies in response to the requirements of
national securities exchanges, such as the NYSE or The Nasdaq Stock Market.
Among the corporate governance measures that are required under the rules of
national securities exchanges and NASDAQ are those that address board of
directors' independence, audit committee oversight, and the adoption of a code
of ethics. While our board of directors has adopted a Code of Ethics and


                                       14
<PAGE>

Business Conduct, we have not yet adopted any of these other corporate
governance measures and, since our securities are not yet listed on a national
securities exchange or Nasdaq, we are not required to do so. It is possible that
if we were to adopt some or all of these corporate governance measures,
shareholders would benefit from somewhat greater assurances that internal
corporate decisions were being made by disinterested directors and that policies
had been implemented to define responsible conduct. For example, in the absence
of audit, nominating and compensation committees comprised of at least a
majority of independent directors, decisions concerning matters such as
compensation packages to our senior officers and recommendations for director
nominees may be made by a majority of directors who have an interest in the
outcome of the matters being decided. Prospective investors should bear in mind
our current lack of corporate governance measures in formulating their
investment decisions.

We may be exposed to potential risks relating to our internal controls over
financial reporting and our ability to have those controls attested to by our
independent auditors.

As directed by Section 404 of the Sarbanes-Oxley Act of 2002 ("SOX 404"), the
Securities and Exchange Commission adopted rules requiring public companies to
include a report of management on the company's internal controls over financial
reporting in their annual reports. In addition, the independent registered
public accounting firm auditing a company's financial statements must also
attest to and report on management's assessment of the effectiveness of the
company's internal controls over financial reporting as well as the operating
effectiveness of the company's internal controls.

While we expect to expend significant resources in developing the necessary
documentation and testing procedures required by SOX 404, there is a risk that
we will not comply with all of the requirements imposed thereby. At present,
there is no precedent available with which to measure compliance adequacy.
Accordingly, there can be no positive assurance that we will receive a positive
attestation from our independent auditors. In the event we identify significant
deficiencies or material weaknesses in our internal controls that we cannot
remediate in a timely manner or we are unable to receive a positive attestation
from our independent auditors with respect to our internal controls, investors
and others may lose confidence in the reliability of our financial statements
and our ability to obtain equity or debt financing could suffer.

                   RISKS RELATED TO THE COMPANY'S COMMON STOCK

The COMPANY DOES NOT EXPECT TO PAY CASH DIVIDENDS IN TH EFORESEEABLE FUTURE.

Company has never paid cash dividends on its common stock and has no plans to do
so in the foreseeable future. The Company intends to retain earnings, if any, to
develop and expand its business.

"PENNY STOCK" RULES MAY MAKE BUYING OR SELLING THE COMMON STOCK DIFFICULT A
SEVERELY LIMIT THEIR MARKET AND LIQUIDITY.

Trading in the Company's common stock is subject to certain regulations adopted
by the SEC commonly known as the "Penny Stock Rules". The Company's common stock
qualifies as penny stock and is covered by Section 15(g) of the Securities and
Exchange Act of 1934, as amended (the "1934 Act"), which imposes additional
sales practice requirements on broker/dealers who sell the Company's common
stock in the market. The "Penny Stock" rules govern how broker/dealers can deal
with their clients and "penny stock". For sales of the Company's common stock,
the broker/dealer must make a special suitability determination and receive from
clients a written agreement prior to making a sale. The additional burdens
imposed upon broker/dealers by the "penny stock" rules may discourage
broker/dealers from effecting transactions in the Company's common stock, which
could severely limit its market price and liquidity. This could prevent
investors from reselling Echo common stock and may cause the price of the common
stock to decline.

                                       15
<PAGE>

Although publicly traded, the Company's common stock has substantially less
liquidity than the average trading market for a stock quoted on other national
exchanges, and our price may fluctuate dramatically in the future.

Our Common Stock is currently quoted on the Pink Sheets. Our Common Stock was
previously listed for trading on the Over-the-Counter Electronic Bulletin Board.
The trading market in the common stock has substantially less liquidity than the
average trading market for companies quoted on other national stock exchanges. A
public trading market having the desired characteristics of depth, liquidity and
orderliness depends on the presence in the marketplace of willing buyers and
sellers of our common stock at any given time. This presence depends on the
individual decisions of investors and general economic and market conditions
over which we have no control. Due to limited trading volume, the market price
of the Company's common stock may fluctuate significantly in the future, and
these fluctuations may be unrelated to the Company's performance. General market
price declines or overall market volatility in the future could adversely affect
the price of the Company's common stock, and the current market price may not be
indicative of future market prices.

ITEM 4. CONTROLS AND PROCEDURES

An evaluation was carried out by the Company's chief executive officer and
treasurer of the effectiveness of the Company's disclosure controls and
procedures (as defined in Rule 13a-15e or 15(d)-15(e) of the Securities Exchange
Act of 1934) as of March 31, 2007. Based upon that evaluation, the chief
executive officer and the treasurer concluded that the design and operation of
these disclosure controls and procedures were effective after giving affect to
the acquisition of Cybrdi, Inc. by the Company and its obligations to comply
with applicable accounting and disclosure requirements.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 that the Company may
have a potential liability from waste disposal in the Casmalia Disposal Site at
Santa Barbara County, California. The Company was given a choice of either
signing an agreement that would toll the statute of limitations for eighteen
(18) months in order to allow the Company to resolve any liability with the
government without incurring costs associated with being named a defendant in a
lawsuit, or becoming an immediate defendant in a lawsuit. The Company signed the
tolling agreement. On November 20, 2001, the tolling agreement was extended for
an additional 18 months. On May 20, 2003 the tolling agreement was again
extended for an additional 18 months and on November 24, 2004 the tolling
agreement was again extended for additional 18 months. On June 29, 2004, the
Company received a proposed settlement from the EPA in the amount of $21,131.
The Company is waiting for communication from the government concerning payment
of the proposed settlement. As of March 31, 2007, the Company has accrued a
sufficient amount to cover any potential liabilities from this matter.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

                                       16
<PAGE>

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. EXHIBITS AND REPORT ON FORM 8-K

(A)      EXHIBITS:

         31.1 Rule 13(a)-14(a)/15(d)-14(a) Certification

         31.2 Rule 13(a)-14(a)/15(d)-14(a) Certification

         32.1 Certification Under Section 906 of the Sarbanes-Oxley Act fof 2002

         32.2 Certification Under Section 906 of the Sarbanes-Oxley Act of 2002

(B)      REPORTS ON FORM 8-K:

None.

                                       17
<PAGE>
                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  CYBRDI, INC.


DATE:  May 21, 2007               By /s/ Yanbiao Bai
                                  ------------------
                                  Yanbiao Bai
                                  Chief Executive Officer and President


DATE:  May 21, 2007               By /s/ Xue Bu
                                  -------------
                                  Xue Bu
                                  Principal Financial Officer

                                       18